DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the...
June 20 2019 - 9:00AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF) a leader in early detection of critical health issues
through the use of its FL
AIRE platform based on
Artificial Intelligence (
AI), announces today the
extension of its technological showcase for the automated detection
of Diabetic Retinopathy at the CHUM (Centre Hospitalier de
l’Université de Montréal) until the end of August 2019.
Technological showcaseLaunched
in June 2018 in collaboration with the ophthalmology and
endocrinology department, the technology showcase has so far
allowed several hundred diabetic patients from the CHUM to access
screening technology. DIAGNOS will continue screening for diabetic
retinopathy until the end of August 2019.
“This technological showcase is very important
to us. We can demonstrate our expertise to our future
Canadian and international clients. We can present the precision of
our algorithms in the detection and classification of the patients
in order of the severity of the disease. This showcase is also
helping us to understand how healthcare professionals integrate
Artificial Intelligence in their practice,” said Yves-Stephane
Couture, Vice President at DIAGNOS.
DIAGNOS has screened to date more than 275,000
diabetic patients. Thanks to the support of the Government of
Quebec and our collaboration with the CHUM, this technological
showcase will allow DIAGNOS to demonstrate our expertise in the
province. We strongly believe this partnership will also help set
up extensive screening campaigns in other Canadian provinces and in
the United States.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024